

Dear All,

Please find the attached investor presentation on acquisition of dermatology and oral solids businesses from Sandoz Inc., USA, which was shared with stock exchanges. We are hosting an investor call on 6th Sep 2018 where the senior management of the company will be answering the participants queries. We cordially invite you to participate in the call.

**The call details are mentioned below:**

Date: Thursday, 6th September 2018  
Time: 05:30 PM (IST)  
Duration: ~1/2 hour

The dial-in details to participate in the call is as under. You may also pre-register in the call through the link mentioned below.

Please dial the below number at least 5 minutes prior to the conference schedule to ensure that you are connected to your call in time.	
<b>Primary Number:</b>	+91 22 6280 1292 / +91 22 7115 8193
<i>The number listed above are universally accessible from all networks and all countries.</i>	
Local Access Number:	+91-7045671221 <i>Available all over India</i>
Toll Free Number:	USA: 1866 746 2133 UK: 0808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448
Pre-register Link (URL)	<a href="http://services.choruscall.in/diamondpass/registration?confirmationNumber=8047377">http://services.choruscall.in/diamondpass/registration?confirmationNumber=8047377</a>

**About Aurobindo Pharma Limited:**

Aurobindo Pharma Limited ([www.aurobindo.com](http://www.aurobindo.com)) (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, Anti-Allergies and Anti-Diabetics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.

Regards,  
Krishna Kiran  
Investor Relations,  
Aurobindo Pharma Ltd